Treace Medical Concepts (TMCI)
NASDAQ:TMCI
Want to see TMCI full AI Analyst Report?
TMCI Stock Chart & Stats
$1.94
-$0.15(-1.96%)
At close: 4:00 PM EST
$1.94
-$0.15(-1.96%)
Day’s Range― - ―
52-Week Range$1.17 - $7.78
Previous CloseN/A
Volume76.56K
Average Volume (3M)918.48K
Market Cap
$130.22M
Enterprise Value$134.22M
Total Cash (Recent Filing)$51.85M
Total Debt (Recent Filing)$13.55M
Price to Earnings (P/E)―
Beta2.38
Next Earnings
Aug 11, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding64,784,440
10 Day Avg. Volume1,009,218
30 Day Avg. Volume918,480
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)1.77
Price to Sales (P/S)0.73
P/FCF Ratio-5.26
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue0.65
Enterprise Value/Gross Profit0.81
Enterprise Value/Ebitda-2.80
Forecast
1Y Price Target
$4.08Price Target Upside110.48% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.91
Revenue Forecast (FY)$205.92M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsConsistently ~80% product gross margins provide durable per-procedure economics that cushion EBITA sensitivity to revenue swings. High gross margin supports long-term operating leverage as adoption grows and helps fund commercialization without immediate margin erosion.
Expanding Product Portfolio And Surgeon AdoptionA broadened portfolio (multiple 2025 launches and planned 2026 launches) plus a growing trained surgeon base creates durable TAM expansion and recurring consumable demand. Greater clinical adoption increases procedure-led revenue resilience over months as install base scales.
Improving Cash Profile And LiquidityMeaningful reduction in cash burn and narrower adjusted EBITDA losses, combined with cash on hand and a sizable committed credit facility, materially extend runway. This funding flexibility supports product launches and commercialization without immediate equity dilution.
Bears Say
Persistent Negative Cash FlowOperating and free cash flow remain chronically negative, forcing reliance on cash reserves and credit. Persistent outflows constrain reinvestment capacity, raise refinancing risk if growth stalls, and limit margin improvements absent continued cash discipline or external funding.
Guidance: Flat-to-Declining Revenue And Mix ShiftManagement's guidance implies near-term top-line pressure and a material Q1 step-down, driven partly by a shift to lower-ASP products. Sustained revenue softness or prolonged lower ASP mix would compress growth runway and delay leverage of the firm's high gross margins into consistent profitability.
Elevated Operating Expenses And Capital PressureHigher operating costs, one-time charges and negative ROE indicate pressure on the capital base and underlying profitability. Continued elevated opex and legal or restructuring costs can erode returns, restrict strategic investments, and prolong dependence on external liquidity.
Treace Medical Concepts News
TMCI FAQ
What was Treace Medical Concepts’s price range in the past 12 months?
Treace Medical Concepts lowest stock price was $1.17 and its highest was $7.78 in the past 12 months.
What is Treace Medical Concepts’s market cap?
Treace Medical Concepts’s market cap is $130.22M.
When is Treace Medical Concepts’s upcoming earnings report date?
Treace Medical Concepts’s upcoming earnings report date is Aug 11, 2026 which is in 92 days.
How were Treace Medical Concepts’s earnings last quarter?
Treace Medical Concepts released its earnings results on May 08, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.308 by $0.028.
Is Treace Medical Concepts overvalued?
According to Wall Street analysts Treace Medical Concepts’s price is currently Undervalued.
Does Treace Medical Concepts pay dividends?
Treace Medical Concepts does not currently pay dividends.
What is Treace Medical Concepts’s EPS estimate?
Treace Medical Concepts’s EPS estimate is -0.29.
How many shares outstanding does Treace Medical Concepts have?
Treace Medical Concepts has 64,784,440 shares outstanding.
What happened to Treace Medical Concepts’s price movement after its last earnings report?
Treace Medical Concepts reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.308. Following the earnings report the stock price went up 4.687%.
Which hedge fund is a major shareholder of Treace Medical Concepts?
Currently, no hedge funds are holding shares in TMCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Treace Medical Concepts Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.08 (110.48% Upside)
$4.08 (110.48% Upside)
Hedge Fund Trend
Increased
By 120.7K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.80%
12-Months-Change
Fundamentals
Return on Equity
-69.50%
Trailing 12-Months
Asset Growth
-10.56%
Trailing 12-Months
Company Description
Treace Medical Concepts
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
TMCI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: the company demonstrated meaningful operational progress — expanding its product portfolio, accelerating surgeon adoption, materially reducing cash burn and improving full-year adjusted EBITDA vs prior year — and secured liquidity. However, these positives are offset by near-term revenue pressure driven by a mix shift toward lower-priced products, market softness in elective foot and ankle procedures, a sizable Q4 GAAP net loss increase, and guidance that implies flat-to-declining revenue for 2026 with an expectation of an adjusted EBITDA loss. Management expects improvements later in 2026 (stronger Q3/Q4) as new higher-ASP products launch and adoption deepens, but the current outlook and recent quarterly results temper the outlook.View all TMCI earnings summariesTMCI Stock 12 Month Forecast
Average Price Target
$4.08
▲(110.48% Upside)
Technical Analysis
Ownership Overview
29.21% Insiders
8.80% Mutual Funds
9.26% Other Institutional Investors
45.46% Public Companies and
Individual Investors